Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas

Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas

Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion resulting in a EUR 150,000 capital increase. This is part of Atlas Special Opportunities, LLC’s EUR 20 million Capital Commitment¹ that will allow Oxurion to focus on developing innovative therapeutics to preserve the vision of elderly people, targeting potential market opportunities of USD 3-6 billion.

Leuven, BELGIUM – 04 March, 2024 – 07.00 PM CET – In accordance with article 15 of the Belgian Act of May 2, 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, Oxurion NV (Euronext Brussels: OXUR) (the “Company” or “Oxurion”), announces the below information, following the issuance of 815,217,391 new ordinary shares on February 29, 2024, for a total amount of EUR 150,000 pursuant to the Capital Commitment entered into with Atlas Special Opportunities, LLC.

Following completion of capital increase through the conversion of the convertible bonds, the total number of shares issued by Oxurion amounts to 5,753,951,723 outstanding ordinary shares carrying voting rights (compared to 4,938,734,332 outstanding ordinary shares previously). This number will be used as the denominator for the calculation of the percentages of shareholdings.

Therefore, Oxurion publishes the following updated information:

Share capital (EUR)	84,056,161.32
Total number of securities with voting rights (all ordinary shares)	5,753,951,723
Total number of ordinary shares (= denominator)	5,753,951,723
Number of outstanding, granted rights to subscribe to securities carrying voting rights not yet issued (excluding any shares resulting (a) from the potential conversion of any convertibles bonds issued on December 20, 2021 to the benefit of Kreos Capital VI (UK) Limited, Pontifax Medison Finance (Israel) L.P. and Pontifax Medison Finance (Cayman) L.P. or (b) from the exercise of any subscription rights issued by the Company to the benefits of employees, consultants or directors of the Company (as they are both currently significantly out-of-the-money):